Stada Arzneimittel, the German pharmaceutical company, reported robust financial results for the first half of 2024, with sales reaching €2.02 billion, a 9% increase compared to the same period in 2023. Earnings before interest, taxes, depreciation, and amortization also grew by 11% to €465.3 million. The company’s growth was driven by strong performances across its three business segments—specialty pharma, generics, and consumer healthcare—with specialty pharma leading the charge due to an expanding biosimilar portfolio and the successful launches of new neurology and nephrology products.
As Stada continues its upward trajectory, its private equity owners, Cinven and Bain Capital, are exploring various strategic options, including a potential sale or initial public offering (IPO). Although there is no definitive update on these plans, CEO Peter Goldschmidt emphasized the company’s focus on maintaining its growth momentum, outpacing competitors, and leveraging its robust pipeline of generic drugs that are poised to enter the market as more original medicines lose exclusivity.
The possibility of a sale has been a topic of discussion since last year, with reports suggesting that Stada could be valued at around €8 billion. Cinven and Bain acquired Stada in 2017 for €5.3 billion, gaining control of one of Europe’s last independent generic drug makers. As talks continue, the future of Stada remains a key point of interest in the pharmaceutical industry.
Click here to read the original news story.